(Q44666887)

5 December 2017

title

Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia (English)

1 reference

5 December 2017

0 references

0 references

6

John H Krystal

1 reference

5 December 2017

Ismene L Petrakis

1

1 reference

5 December 2017

Stephanie O'Malley

2

1 reference

5 December 2017

Bruce Rounsaville

3

1 reference

5 December 2017

James Poling

4

1 reference

5 December 2017

Colette McHugh-Strong

5

1 reference

5 December 2017

VA Naltrexone Study Collaboration Group

7

1 reference

5 December 2017

publication date

21 November 2003

1 reference

5 December 2017

1 reference

5 December 2017

volume

172

1 reference

5 December 2017

issue

3

1 reference

5 December 2017

page(s)

291-297

1 reference

https://scigraph.springernature.com/pub.10.1007/s00213-003-1658-9

5 December 2017

exact match

0 references

cites work

Selective and enduring deficits in spatial learning after limited neonatal binge alcohol exposure in male rats

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1658-9

The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1658-9

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1658-9

Amisulpride does not prevent relapse in primary alcohol dependence: results of a pilot randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1658-9

Experience of a "slip" among alcoholics treated with naltrexone or placebo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1658-9

Short-term naloxone administration in schizophrenic and manic patients. A World Health Organization Collaborative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1658-9

Matching Alcoholism Treatments to Client Heterogeneity: Project MATCH posttreatment drinking outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1658-9

The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1658-9

Naltrexone-induced alterations in human ethanol intoxication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1658-9

Naltrexone in the treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1658-9

Effect of naltrexone on alcohol "high" in alcoholics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1658-9

Flupenthixol decanoate and relapse prevention in alcoholics: results from a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1658-9

The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1658-9

Naltrexone and coping skills therapy for alcohol dependence. A controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1658-9

CSF monoamine metabolite and beta endorphin levels in recently detoxified alcoholics and healthy controls: prediction of alcohol cue-induced craving?

21 January 2018

1 reference

12 December 2020

The development of a cocaine craving questionnaire.

1 reference

12 December 2020

Substance misuse in patients with schizophrenia: epidemiology and management

1 reference

12 December 2020

Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study

1 reference

12 December 2020

Effect of tryptophan depletion on alcohol cue-induced craving in abstinent alcoholic patients

1 reference

12 December 2020

Alcohol dependence and hospitalization in schizophrenia

1 reference

12 December 2020

The effect of tryptophan depletion on alcohol self-administration in non-treatment-seeking alcoholic individuals

1 reference

12 December 2020

Repeated naloxone administration in schizophrenia: a phase II World Health Organization Study

1 reference

12 December 2020

Naltrexone increases the latency to drink alcohol in social drinkers.

1 reference

12 December 2020

Metabolic interaction between perphenazine and disulfiram

1 reference

12 December 2020

Random regression models for multicenter clinical trials data

1 reference

12 December 2020

Naltrexone augmentation of neuroleptics in schizophrenia

1 reference

12 December 2020

The Hopkins Symptom Checklist (HSCL): A self-report symptom inventory

1 reference

12 December 2020

Disulfiram treatment for alcoholism in severe mental illness

1 reference

12 December 2020

Tiapride in the long-term management of alcoholics of anxious or depressive temperament.

1 reference

12 December 2020

Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes

1 reference

12 December 2020

Naltrexone utility in depressed alcoholics.

1 reference

12 December 2020

Neurobiology of addiction. Toward the development of new therapies

1 reference

12 December 2020

Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis

1 reference

12 December 2020

Use of naltrexone in the treatment of alcohol use disorders in patients with concomitant major mental illness

1 reference

12 December 2020

Naltrexone in the treatment of alcohol dependence

1 reference

12 December 2020

Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis.

1 reference

12 December 2020

10.1007/S00213-003-1658-9

Identifiers

DOI

1 reference

5 December 2017

1 reference